CN107519142A - 一种盐酸环苯扎林舌下片及其制备方法 - Google Patents

一种盐酸环苯扎林舌下片及其制备方法 Download PDF

Info

Publication number
CN107519142A
CN107519142A CN201710736021.3A CN201710736021A CN107519142A CN 107519142 A CN107519142 A CN 107519142A CN 201710736021 A CN201710736021 A CN 201710736021A CN 107519142 A CN107519142 A CN 107519142A
Authority
CN
China
Prior art keywords
cyclobenzaprine hydrochloride
sublingual tablet
diluent
disintegrant
cyclobenzaprine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710736021.3A
Other languages
English (en)
Other versions
CN107519142B (zh
Inventor
王明刚
陈阳生
刘晓霞
孙桂玉
臧云龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Original Assignee
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Chia Tai Haier Pharmaceutical Co Ltd filed Critical Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Priority to CN201710736021.3A priority Critical patent/CN107519142B/zh
Publication of CN107519142A publication Critical patent/CN107519142A/zh
Application granted granted Critical
Publication of CN107519142B publication Critical patent/CN107519142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种盐酸环苯扎林舌下片及其制备方法,属于药物制剂领域。本发明的盐酸环苯扎林舌下片优选包含盐酸环苯扎林25%,稀释剂40%,崩解剂20%,矫味剂3%,本发明采用特殊的重量比为3:2:5的蔗糖、乳糖和甘露醇作为稀释剂,以及微晶纤维素10‑20%和羧甲基纤维素钙C 10‑20%作为崩解剂,由此制备的舌下片崩解能够满足时限要求,采用舌下片的新颖形式,在服用时至于口腔使其崩解服用,配合优选的薄荷香精,能够增强消费者的用药感受,质量稳定,效果显著。

Description

一种盐酸环苯扎林舌下片及其制备方法
技术领域
本发明涉及药物制剂领域,具体涉及一种盐酸环苯扎林舌下片及其制备方法。
背景技术
在生活节奏越来越快的现代社会,腰酸背痛是常见的疾病之一,人们一般都以休息的方式对待,然而休息并不能解决根本问题,疼痛症状会日益加重,直到痛到让你根本无法工作,不但花费大比医疗费用,而且长期和大量的误工会影响社会生产总值。
急性疼痛指疼痛时间少于3个月的后背、下背疼痛,最初的感觉为肌肉痉挛,肌肉酸痛,局部活动受限,症状一般持续几周,影响日常生活质量和工作效率,如果治疗不当,会逐渐转化为慢性疼痛,进一步恶化,情况会更加严重。因为肌肉的协调失常,常造成脊柱功能恶化,而且时间可能极为漫长而不易被人警觉,一开始不一定会痛,常常只有不正常的位移感觉,也因不易察觉,当机体感觉有疼痛症状时,往往已经是积劳成疾的地步,大多已经有一定的伤害产生。而且如果继续忽略病情,耽误治疗,初期的病理变化进一步发展,可能会造成严重的脊柱损害(椎间盘突出、脊柱滑脱、椎间板退化)和骨盆腔疾病等严重的后果,影响站立和活动,被迫长期卧床。
目前,中国繁荣的经济发展前景同时带动了意识形态领域的进展,健康已经成为一种时尚,腰酸腿痛已经不在单纯是劳累的代名词,更多的人将其列入就医的原因之一,希望通过有效的药物或者治疗缓解症状,提高生活质量,同时防患与未然,告别亚健康状态,保持健康的体质。而目前医疗市场并未适应这种新的趋势,对于背痛的治疗还限于休息和物理治疗的范畴,开发确切疗效的中枢性肌肉松弛性药物有较好前景。
盐酸环苯扎林(Cyclobenzaprine hydrochloride),化学名为5-(3-二甲氨基亚丙基)-二苯并[a,e]环庚三烯盐酸盐,结构式如下所示:
盐酸环苯扎林最早由Merk公司研制开发,1978年,盐酸环苯扎林片在美国上市,规格为5mg、10mg,用于缓解急性疼痛性肌肉骨骼疾病伴随的肌肉痉挛,目前仍是美国最常用的肌肉松弛剂之一,在国内尚未上市。盐酸环苯扎林缓释剂于2007年8月首次获美国FDA批准上市,为美国FDA批准的唯一一个每日给药一次的肌松药,作为休息和理疗的辅助治疗,用于缓解急性、疼痛性肌肉骨骼疾病相关的肌肉痉挛及其伴随的疼痛、触痛和活动受限等症状或体征,临床应用多年,安全有效。
本发明即是为了弥补现有技术的不足,提供一种新型的盐酸环苯扎林制剂。
发明内容
本发明的目的即是提供一种新型的安全有效,质量稳定,效果显著的盐酸环苯扎林舌下片剂及其制备方法。
本发明解决该技术问题的技术方案是:
一种盐酸环苯扎林舌下片,由包括以下重量百分比的组分制备而成:盐酸环苯扎林20-30%,稀释剂40-50%,崩解剂20-40%,矫味剂2-5%,香精适量,防腐剂适量,蒸馏水适量。各组分的重量百分比优选为:盐酸环苯扎林23-28%,稀释剂43-46%,崩解剂22-38%,矫味剂3-5%。进一步优选为:盐酸环苯扎林25%,稀释剂40%,崩解剂20%,矫味剂3%。
所述稀释剂由蔗糖、乳糖和甘露醇组成,其重量比为3:2:5。
所述崩解剂包括微晶纤维素10-20%和羧甲基纤维素钙C 10-20%。
所述矫味剂和香精可选择本领域常用的组分,矫味剂包括阿司帕坦,糖精钠,山梨醇等,香精包括橙子香精,薄荷香精等。
所述香精优选为薄荷香精。
本发明同时提供了一种盐酸环苯扎林舌下片的制备方法,其特征在于,其操作步骤为:
(1)按比例称取稀释剂,将其混合均匀,过80目筛;
(2)将配制好的稀释剂与盐酸环苯扎林、崩解剂、矫味剂、香精以及防腐剂混合均匀,加入蒸馏水造粒,加入润滑剂,压片即得。
本发明取得了如下的有益效果:
(1)对于镇痛类活性成分盐酸环苯扎林,本发明采用舌下片的新颖形式,在服用时置于口腔使其崩解服用,配合优选的薄荷香精,能够增强消费者的用药感受。
(2)本发明采用特殊的重量比为3:2:5的蔗糖、乳糖和甘露醇作为稀释剂,以及微晶纤维素10-20%和羧甲基纤维素钙C 10-20%作为崩解剂,由此制备的舌下片崩解能够满足时限要求,并且质量稳定,效果显著。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。除非另外说明,否则所有的百分数、比率、比例或份数按重量计。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1
按如下配比称取各组分:盐酸环苯扎林20%,重量比为3:2:5的蔗糖-乳糖-甘露醇40%,微晶纤维素15%,羧甲基纤维素钙C 10%,糖精钠3%,橙子香精适量,山梨酸适量,蒸馏水适量。按比例称取稀释剂,将其混合均匀,过80目筛;将配制好的稀释剂与盐酸环苯扎林、崩解剂、矫味剂、香精以及防腐剂混合均匀,加入蒸馏水造粒,加入润滑剂,压片即得。
实施例2
盐酸环苯扎林25%,重量比为3:2:5的蔗糖-乳糖-甘露醇40%,微晶纤维素10%,羧甲基纤维素钙C 10%,糖精钠3%,橙子香精适量,山梨酸适量,蒸馏水适量。按比例称取稀释剂,将其混合均匀,过80目筛;将配制好的稀释剂与盐酸环苯扎林、崩解剂、矫味剂、香精以及防腐剂混合均匀,加入蒸馏水造粒,加入润滑剂,压片即得。
实施例3
盐酸环苯扎林30%,重量比为3:2:5的蔗糖-乳糖-甘露醇45%,微晶纤维素10%,羧甲基纤维素钙C 12%,糖精钠1%,橙子香精适量,山梨酸适量,蒸馏水适量。按比例称取稀释剂,将其混合均匀,过80目筛;将配制好的稀释剂与盐酸环苯扎林、崩解剂、矫味剂、香精以及防腐剂混合均匀,加入蒸馏水造粒,加入润滑剂,压片即得。
实验例4崩解时限试验
按中国药典2010版崩解时限检查法对实施例1-3的盐酸环苯扎林舌下片进行检查,并以盐酸环苯扎林普通市售片作为对照,结果如表1所示:
表1盐酸环苯扎林舌下片崩解时限试验结果
结果显示,本发明的盐酸环苯扎林舌下片在2分钟内能完成崩解,满足舌下片的崩解时限要求。
实施例5体外溶出度试验
按中国药典2010版溶出度测定法对实施例1-3的盐酸环苯扎林舌下片进行检查,并以盐酸环苯扎林普通市售片作为对照,结果如表2所示:
表2盐酸环苯扎林舌下片溶出度试验结果
结果显示,本发明的盐酸环苯扎林舌下片溶出较普通片快,满足舌下片要求。
实施例6稳定性实验
1.影响因素试验
加速稳定性试验
将实施例2中的盐酸环苯扎林舌下片分别置低温(4℃)、强光(4500lx)、高温(60℃)及高湿(RH75%)条件下10天,分别于第0、5、10天取样,检测性状、含量、有关物质等各项质量指标,结果见表3。
表3盐酸环苯扎林舌下片影响因素试验结果
结果表明:盐酸环苯扎林舌下片在高温(60℃)、低温(4℃)、强光(4500lx)、高湿(RH75%)条件下放置10天,检测各项质量指标,与0天比较,除高温(60℃)有关物质略有增加以及盐酸环苯扎林的含量有所下降外,其他各项质量指标均无明显变化。
2.加速试验
将实施例2所得盐酸环苯扎林舌下片置于40℃、RH20%的恒温、恒湿箱中6个月,分别于第0、1、2、3、6个月取样,测定性状、含量、有关物质等各项质量指标,结果见表4。
表4盐酸环苯扎林舌下片加速试验结果
时间(月) 性状 有关物质(%) 含量(%)
0 白色 0.17 100.02
1 白色 0.22 100.12
2 白色 0.41 100.41
3 白色 0.50 100.14
6 白色 0.56 100.11
结果表明:盐酸环苯扎林舌下片在40℃、RH20%的条件下放置6个月,与0个月比较,除有关物质略有增加外,其他各项质量指标均无明显变化,质量稳定可靠,符合规定。
3.长期试验
将实施例2所得盐酸环苯扎林舌下片置于25℃、RH60%的环境中,分别于第0、3、6、9、12、18、24个月取样,检查性状、含量、有关物质等各项质量指标,结果见表5。
表3盐酸环苯扎林舌下片长期试验结果
结果表明:盐酸环苯扎林舌下片在25℃、RH60%环境中放置36个月,除了颗粒吸潮以外,各项指标与0月比较均无明显变化,质量稳定可靠,符合规定。
以上所述仅为本发明的较佳实施例而已,并非用以限定本发明的实质技术内容范围,本发明的实质技术内容是广义地定义于申请的权利要求范围中,任何他人完成的技术实体或方法,若是与申请的权利要求范围所定义的完全相同,也或是一种等效的变更,均将被视为涵盖于该权利要求范围之中。

Claims (8)

1.一种盐酸环苯扎林舌下片,其特征在于,由包括以下重量百分比的组分制备而成:盐酸环苯扎林20-30%,稀释剂40-50%,崩解剂20-40%,矫味剂2-5%,香精适量,防腐剂适量,蒸馏水适量。
2.根据权利要求1所述的盐酸环苯扎林舌下片,其特征在于,所述稀释剂由蔗糖、乳糖和甘露醇组成。
3.根据权利要求2所述的盐酸环苯扎林舌下片,其特征在于,所述蔗糖-乳糖-甘露醇的重量比为3:2:5。
4.根据权利要求1-3中任一项所述的盐酸环苯扎林舌下片,其特征在于,所述崩解剂包括微晶纤维素10-20%和羧甲基纤维素钙C 10-20%。
5.根据权利要求1-4中任一项所述的盐酸环苯扎林舌下片,其特征在于,所述香精优选为薄荷香精。
6.根据权利要求1-4中任一项所述的盐酸环苯扎林舌下片,其特征在于,所述组分的重量百分比优选为:盐酸环苯扎林23-28%,稀释剂43-46%,崩解剂22-38%,矫味剂3-5%。
7.根据权利要求1-6中任一项所述的盐酸环苯扎林舌下片,其特征在于,所述组分的重量百分比优选为:盐酸环苯扎林25%,稀释剂40%,崩解剂20%,矫味剂3%。
8.根据权利要求1-7任一项所述的盐酸环苯扎林舌下片的制备方法,其特征在于,其操作步骤为:
(1)按比例称取稀释剂,将其混合均匀,过80目筛;
(2)将配制好的稀释剂与盐酸环苯扎林、崩解剂、矫味剂、香精以及防腐剂混合均匀,加入蒸馏水造粒,加入润滑剂,压片即得。
CN201710736021.3A 2017-08-24 2017-08-24 一种盐酸环苯扎林舌下片及其制备方法 Active CN107519142B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710736021.3A CN107519142B (zh) 2017-08-24 2017-08-24 一种盐酸环苯扎林舌下片及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710736021.3A CN107519142B (zh) 2017-08-24 2017-08-24 一种盐酸环苯扎林舌下片及其制备方法

Publications (2)

Publication Number Publication Date
CN107519142A true CN107519142A (zh) 2017-12-29
CN107519142B CN107519142B (zh) 2021-02-26

Family

ID=60682090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710736021.3A Active CN107519142B (zh) 2017-08-24 2017-08-24 一种盐酸环苯扎林舌下片及其制备方法

Country Status (1)

Country Link
CN (1) CN107519142B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684550A (zh) * 2012-06-15 2015-06-03 通尼克斯制药有限公司 用于跨粘膜吸收的组合物和方法
CN105395507A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种盐酸环苯扎林缓释片

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684550A (zh) * 2012-06-15 2015-06-03 通尼克斯制药有限公司 用于跨粘膜吸收的组合物和方法
CN105395507A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种盐酸环苯扎林缓释片

Also Published As

Publication number Publication date
CN107519142B (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
Hays et al. Psychometric properties of the medical outcomes study sleep measure
Kowalczyk et al. Sex differences and hormonal influences on response to cold pressor pain in humans
Coffey et al. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment
Badia et al. Validity and reliability of the Spanish version of the Psychological General Well-Being Index
Florea et al. The effect of vortioxetine on health-related quality of life in patients with major depressive disorder
Bao et al. Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson’s disease
Liu et al. A Meta‐Analysis of the Effects of Tai Chi on Glucose and Lipid Metabolism in Middle‐Aged and Elderly Diabetic Patients: Evidence from Randomized Controlled Trials
CN107519142A (zh) 一种盐酸环苯扎林舌下片及其制备方法
Chapelsky et al. A dose proportionality study of eprosartan in healthy male volunteers
Andia et al. Gender differences in schizophrenia: A literature review
CN107496355A (zh) 一种盐酸环苯扎林舌下喷雾剂及其制备方法
Carneiro et al. Different load intensity transition schemes to avoid plateau and no-response in lean body mass gain in postmenopausal women
Mishra et al. A clinical study of Ashwagandha ghrita and Ashwagandha granules for its Brumhana and Balya effect
Fernández-Sánchez et al. Effect of Acute Caffeine Intake on Fat Oxidation Rate during Fed-State Exercise: A Systematic Review and Meta-Analysis
Maxwell et al. Allometric scaling of kidney function in green iguanas
Kwon et al. Effects of the combination herbal extract on working memory and white matter integrity in healthy individuals with subjective memory complaints: A randomized, double-blind, placebo-controlled clinical trial
Phua et al. Two instances of Chinese herbal medicine poisoning in Singapore
Li et al. An evaluation of self-efficacy and satisfaction with the effectiveness of Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with chronic obstructive pulmonary disease
Yang The Role and Mechanism of the Diabetes Control Based on the Association Rule Apriori Algorithm
Karmakar Non communicable diseases risk factors among students of a government medical college in Kolkata
Zhai et al. Bioequivalence study of amitriptyline hydrochloride tablets in healthy Chinese volunteers under fasting and fed conditions
Hayashi et al. Oxatomide for stable asthma in adults and children
Goyal et al. A clinical study on the role of Agnimanthadi compound in the management of Sthaulya (obesity)
Hart et al. Social physique anxiety scale
Kong et al. Randomized, multicenter clinical study of tratinterol hydrochloride tablets for the treatment of bronchial asthma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 266103 block L, Haier Industrial Park, Laoshan District, Qingdao City, Shandong Province

Applicant after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd.

Address before: 266103 block L, Haier Industrial Park, Laoshan District, Qingdao City, Shandong Province

Applicant before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd.

Address after: No.3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province 266426

Applicant after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd.

Address before: 266103 block L, Haier Industrial Park, Laoshan District, Qingdao City, Shandong Province

Applicant before: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant